Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
1.Drug efflux by P-glycoprotein (P-gp) is a common resistance mechanism of breast cancer cells to paclitaxel, the primary chemotherapy in breast cancer.
|
27189791 |
2017 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
2D-PAGE and MALDI-TOF/MS-based proteomics approach were used to separate and identify differentially expressed proteins between MCF-7 and MCF-7/ADR, a p-glycoprotein-overexpressing adriamycin-resistance breast cancer cell line.
|
19764771 |
2009 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Breast cancer tumor resistance is mainly associated with overexpression of P-gp/MDR1.
|
21237614 |
2011 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Breast cancer cell lines and tissue specimens (obtained from chemotherapy-sensitive or resistant patients) as well as a normal breast cell line were used to assess expression of miR-195, Raf-1, Bcl-2 and P-glycoprotein mRNA and/or mRNA. miR-195 mimics, inhibitor and Raf-1 siRNA were used to transfect breast cancer MCF-7 and MCF-7/ADR cells (an Adriamycin-resistant MCF-7 subline) for cell viability, apoptosis and gene expression analysis.
|
23760062 |
2013 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
P-glycoprotein (P-gp) / MDR1, MRP1 and LRP may play more important roles than BCRP in chemotherapy of human breast carcinoma.
|
11346468 |
2001 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
MDR1/P-glycoprotein (P-Gp) over-expression confers multidrug resistance in vitro and might play a role in clinical breast cancer.
|
11391630 |
2001 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
P-glycoprotein modulates ceramide-mediated sensitivity of human breast cancer cells to tubulin-binding anticancer drugs.
|
12467215 |
2002 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
MDR1 USP activation is a surrogate marker for breast carcinoma progression and can be used as a marker to study breast cancer susceptibility.
|
15102684 |
2004 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
MDR1 gene expression and prognostic factors in primary breast carcinomas.
|
1835847 |
1991 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
MDR1 (C3435T) polymorphism: relation to the risk of breast cancer and therapeutic outcome.
|
19752884 |
2010 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
ABCB1, βI, and βIII tubulin might contribute to the MDR of MCF7/DOC and be potential therapeutic targets for overcoming MDR of breast cancer.
|
24894670 |
2014 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
MDR1 C3435T polymorphism in Mexican patients with breast cancer.
|
25062490 |
2014 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
ABCB1 polymorphism as prognostic factor in breast cancer patients treated with docetaxel and doxorubicin neoadjuvant chemotherapy.
|
25410489 |
2015 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
ABCB1 polymorphisms may influence the extent of chemotherapy-induced neutropenia in AC combination-treated patients with breast cancer.
|
25989890 |
2015 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
ABCB1 gene polymorphisms and response to chemotherapy in breast cancer patients: A meta-analysis.
|
29113667 |
2017 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Doxorubicin resistance in breast cancer cells is mediated by extracellular matrix proteins.
|
29304770 |
2018 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Doxorubicin resistance in breast cancer: A novel role for the human protein AHNAK.
|
29309757 |
2018 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
mdr1 mRNA expression by RT-PCR in patients with primary breast cancer submitted to neoadjuvant therapy.
|
9285118 |
1997 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
A P-glycoprotein- and MRP1-independent doxorubicin-resistant variant of the MCF-7 breast cancer cell line with defects in caspase-6, -7, -8, -9 and -10 activation pathways.
|
15015586 |
2004 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
A novel semisynthetic taxane, 2-debenzoyl-2-(3-azidobenzyl)-10-propionyldocetaxel (Yg-3-46a) was shown to be highly cytotoxic to breast cancer cell lines MCF-7 and MCF/ADR which overexpressed P-gp via long term culture with doxorubicin, and cervical cancer cell lines Hela and Hela/βIII which overexpressed βIII-tubulin via stable transfection with TUBB3 gene. siRNA transfection experiments also confirmed that Yg-3-46a can circumvent P-gp and β-III tubulin mediated drug resistance.
|
23941826 |
2013 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Acquisition of docetaxel resistance in breast cancer cells reveals upregulation of ABCB1 expression as a key mediator of resistance accompanied by discrete upregulation of other specific genes and pathways.
|
25596703 |
2015 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Aldo-keto reductase 1C3 (AKR1C3) is associated with the doxorubicin resistance in human breast cancer via PTEN loss.
|
25661377 |
2015 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Although many research showed that GCS could affect mdr1 in cancer cells, nobody knows that whether mdr1 can affect GCS in breast cancer.Our study aims to verify that.
|
21538359 |
2011 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Among all analyzed genes, only CYP1B1 and ABCB1 resulted the strongest candidates to become biomarkers of clinical response to taxane therapy in breast cancer, although their utilization still remains an experimental procedure.
|
26198313 |
2015 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Among the 213 breast carcinomas tested, 113 (53%) were P-gp positive, but in 28% of the tumors, the immunostained surface accounted for less than 5% of the total area stained.
|
7932810 |
1994 |